EUCTR2019-002611-26-BE进行中（未招募）1 期
A Long-term Follow-up Study of Patients in the Clinical Trials forSpinal Muscular Atrophy Receiving AVXS-101 - not applicable
ovartis Gene Therapies, Inc.0 个研究点目标入组 308 人开始时间: 2020年1月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 308
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •> Patients with SMA (with 1, 2 or 3copies of SMN2) who received AVXS-101 gene replacement therapy in an AveXis clinical study
- •> Patient/parent/legal guardian willing and able to complete the informed consent process and comply with study procedures and visit schedule
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 308
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 64
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Parent/legal guardian unable or unwilling to participate in the long-term follow-up safety study
研究者
相似试验
招募中
1 期
ot applicableMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2019-002611-26-ITAVEXIS, INC.308
进行中（未招募）
1 期
/AMedDRA version: 20.0Level: LLTClassification code: 10079413Term: Spinal muscular atrophy type I Class: 10010331MedDRA version: 20.0Level: LLTClassification code: 10079415Term: Spinal muscular atrophy type III Class: 10010331MedDRA version: 20.0Level: LLTClassification code: 10079416Term: Spinal muscular atrophy type II Class: 10010331Spinal Muscular AtrophyCTIS2024-513086-39-00ovartis Pharma AG131
进行中（未招募）
1 期
ot applicableSpinal Muscular AtrophyEUCTR2019-002611-26-GBAveXis, Inc.308
进行中（未招募）
1 期
ot applicableSpinal Muscular AtrophyEUCTR2019-002611-26-FRAveXis, Inc.308
进行中（未招募）
1 期
ot applicableSpinal Muscular AtrophyEUCTR2019-002611-26-ESAveXis, Inc.308